Ascelia Pharma says FDA Orviglance concerns center on image reading process, plans Type A meeting

• Ascelia Pharma issued a clarification on the FDA Complete Response Letter for Orviglance, ahead of a planned Type A meeting to seek an expedited path forward.
• Clinical concerns were framed as tied to the image-reading process; the initial reads were deemed unusable for efficacy conclusions.
• A re-read used new independent, blinded readers under predefined procedures; related approach was discussed with the FDA and incorporated into the NDA.
• Separately, the FDA raised product documentation questions; these are expected to be addressed in the near term.
• A further update is planned following the FDA meeting and receipt of official minutes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascelia Pharma AB published the original content used to generate this news brief on July 12, 2026, and is solely responsible for the information contained therein.